

Practitioner's Docket No. MPI00-438P1RM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Kapeller-Libermann, Rosana (as amended)		
Application No.:	10/044,205	Group No.:	1642
Filed:	October 22, 2001	Examiner:	Yu, Misook
For:	METHODS AND COMPOSITIONS OF HUMAN 69087 NUCLEIC ACIDS AND USES THEREOF (as amended)		

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Confirmation No. 9746

TRANSMITTAL OF PAYMENT OF ISSUE FEE AND AMENDMENTS AFTER ALLOWANCE

1. Transmitted herewith for this application is/are:
- a. This Transmittal (2 pages - in duplicate);
 - b. Part B – Fees Transmittal (1 page - in duplicate);
 - c. Letter Accompanying Amendment after Allowance (37 CFR §1.312) (2 pages);
 - d. Amendment after Allowance (37 CFR §1.312) (3 pages);
 - e. Amendment and Processing Fee Deleting Correctly Named Persons Who are Not Inventor(s) of Invention Now Being Claimed (2 pages – in duplicate); and
 - f. Return Postcard.

STATUS

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail.

- ☒ as "Express Mail Post Office to Addressee"
Mailing Label No. EV512402800US

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: June 28, 2005

Sean Hunziker

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI00-438P1RM

2. Applicant is other than a small entity.
3. Applicant hereby pays the issue fee for the attached Issue Fee Transmittal PTOL-85.
4. Fee (37 C.F.R. Section 1.18(a)):

Regular

Application status is other than a small entity--fee:	\$1,400.00
Publication Fee	\$300.00
Advance Order – patent copies (2)	\$6.00

5. Payment of issue fee:

Charge Account No. 501668 the sum of \$1,706.00. (A duplicate of this request is attached.)

FEE DEFICIENCY


6. If any additional extension and/or fee is required, charge Account No. 501668.
If any additional fee for claims is required, charge Account No. 501668.

June 28, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By 

Kerri Pollard Schray
Registration No. 47,066
40 Landsdowne Street
Cambridge, MA 02139
Telephone – (617) 551-3676
Facsimile – (617) 551-8820



Practitioner's Docket No. MPI00-438P1RM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Base application of:	Kapeller-Libermann, Rosana (as amended)		
Application No.:	10/044,205	Group No.:	1642
Filed:	October 22, 2001	Examiner:	Yu, Misook
For:	METHODS AND COMPOSITIONS OF HUMAN 69087 NUCLEIC ACIDS AND USES THEREOF (as amended)		

Confirmation No.: 9746

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

LETTER ACCOMPANYING AMENDMENT AFTER ALLOWANCE
(37 C.F.R. Section 1.312)

1. Please make the amendments shown in the attached papers in this application in the

- ☒ title
- ☒ abstract.
- ☒ specification.
- ☐ drawings.
- ☐ claims.

2. Type of amendment:

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail.

- ☒ as "Express Mail Post Office to Addressee"
Mailing Label No. EV512402800US

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker

(type or print name of person certifying)

Date: June 28, 2005

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI00-438P1RM

☒ Correction of formal matters
As shown in the remarks of the attached paper, these (1) are needed for proper disclosure or protection of the invention and (2) require no substantial amount of additional work on the part of the PTO.

☐ Other (affects the disclosure, the scope of any claim or adds a claim) (M.P.E.P. Section 714.16, 7th ed.)
As shown in the remarks in the attached supplemental page(s), there is stated the reason (1) why the amendment is needed, (2) why the proposed amended or new claims require no additional search or examination, (3) why the claims are patentable, and (4) why they were not earlier presented.

3. The issue fee:

☐ has not been paid.
☒ is paid separately herewith.
☐ was paid on _____ .

4. Request for Entry of Amendments:


(a) ☒ Because the issue fee has been paid or is paid herewith, the applicant hereby requests entry of the attached amendments. (37 C.F.R. Section 1.312).

5. Fees:

☒ Please charge Account 501668 for any fees that may be required by the filing of this paper.

June 28, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By 
Kerri Pollard Schray
Registration No. 47,066
40 Landsdowne Street
Cambridge, MA 02139
Telephone – (617) 551-3676
Facsimile – (617) 551-8820